HematopoieticTransplantationGraft versusDonorMortalityBone marrowEngraftmentTrialsImmuneSurvivalGVHDTreatmentBiologyTherapeuticPatientsResultsPatientTypeHematopoietic cell transplantationAcute LymphoblProgenitor cellsRemissionPeripheralImmunotherapy2019BonePhase I clinical studyLineagesTherapiesPathologyOutcomesPredominantlyInflammatoryImmuneStudyHumanResearchStudiesProfile
Hematopoietic18
- Mesenchymal stem cells (MSCs) and hematopoietic stem cells (HSCs) have been shown to counter rheumatoid arthritis, autoimmune hepatitis, and systemic sclerosis [ 8 ]. (biomedcentral.com)
- The Hematopoietic stem cell transplantation (HSCT) is used in children as a definitive treatment for various oncological, immune deficiencies, hemoglobinopathy, and malignancies diseases that involve the hematological system, congenital metabolism disorders, among others. (bvsalud.org)
- The allogeneic HSCT was the most frequently performed (57.14%) and the most used source of Hematopoietic progenitor cells (HPC) was the peripheral blood (54.29%) and 5.71% of these patients developed the Graft versus Host Disease (GVHD), of which one was affected by acute GVHD and another by chronic GVHD. (bvsalud.org)
- Hematopoietic Stem Cell Transplantation. (bvsalud.org)
- Hematopoietic stem cell transplantation not responded to other therapeutic modalities, with (HSCT) is used in children as a definitive treatment an increase in survival after transplantation, for different oncological, immune deficiencies, contributing to its use (YEILIPEK, 2014). (bvsalud.org)
- [ 8 ] Immune reconstitution with hematopoietic stem cell transplantation is the treatment of choice. (medscape.com)
- Fludarabine and melphalan-based conditioning for patients with advanced hematological malignancies relapsing after a previous hematopoietic stem cell transplant. (uchicago.edu)
- Outcomes of patients with AML and MDS who relapse or progress after reduced intensity allogeneic hematopoietic cell transplantation. (uchicago.edu)
- Performance status and comorbidity predict transplant-related mortality after allogeneic hematopoietic cell transplantation. (uchicago.edu)
- Phase I study of dose-escalated busulfan with fludarabine and alemtuzumab as conditioning for allogeneic hematopoietic stem cell transplant: reduced clearance at high doses and occurrence of late sinusoidal obstruction syndrome/veno-occlusive disease. (uchicago.edu)
- Treatment of therapy-related myeloid neoplasms with high-dose cytarabine/mitoxantrone followed by hematopoietic stem cell transplant. (uchicago.edu)
- Identification by random forest method of HLA class I amino acid substitutions associated with lower survival at day 100 in unrelated donor hematopoietic cell transplantation. (uchicago.edu)
- Phase I-II study of clofarabine-melphalan-alemtuzumab conditioning for allogeneic hematopoietic cell transplantation. (uchicago.edu)
- Pretreatment C-reactive protein is a predictor for outcomes after reduced-intensity allogeneic hematopoietic cell transplantation. (uchicago.edu)
- Clinicopathologic features of late-onset veno-occlusive disease/sinusoidal obstruction syndrome after high dose intravenous busulfan and hematopoietic cell transplant. (uchicago.edu)
- Identifying familial myelodysplastic/acute leukemia predisposition syndromes through hematopoietic stem cell transplantation donors with thrombocytopenia. (uchicago.edu)
- National Cancer Institute's First International Workshop on the Biology, Prevention, and Treatment of Relapse after Allogeneic Hematopoietic Stem Cell Transplantation: summary and recommendations from the organizing committee. (uchicago.edu)
- BACKGROUND: Graft-versus-host disease (GVHD), particularly acute digestive GVHD (aDGVHD), is a severe complication of allogeneic hematopoietic stem cell transplantation (allo-HSCT). (bvsalud.org)
Transplantation10
- In clinical trials, stem cell transplantation reduced the CD activity index (SMD − 2.10, P = 0.000), the CD endoscopic index of severity (SMD − 3.40, P = 0.000) and simplified endoscopy score for CD (SMD − 1.71, P = 0.000) and improved the inflammatory bowel disease questionnaire score (SMD 1.33, P = 0.305) compared to control values. (biomedcentral.com)
- Stem cell transplantation is a valuable supplementary therapy for CD. (biomedcentral.com)
- Allogeneic blood cell transplantation following reduced-intensity conditioning is effective therapy for older patients with myelofibrosis with myeloid metaplasia. (uchicago.edu)
- Autologous and allogeneic transplantation for aggressive NHL. (uchicago.edu)
- Long-term follow-up of nonmyeloablative allogeneic stem cell transplantation for renal cell carcinoma: The University of Chicago Experience. (uchicago.edu)
- Impact of disease burden at time of allogeneic stem cell transplantation in adults with acute myeloid leukemia and myelodysplastic syndromes. (uchicago.edu)
- Allogeneic stem cell transplantation with alemtuzumab-based conditioning for patients with advanced chronic myelogenous leukemia. (uchicago.edu)
- Successful allogeneic transplantation of patients with suspected prior invasive mold infection. (uchicago.edu)
- Second autologous stem cell transplantation for relapsed lymphoma after a prior autologous transplant. (uchicago.edu)
- Graft-versus-host disease is a common complication following allogeneic hematopoetic stem cell transplantation that can affect multiple organ systems, including the eyes. (bvsalud.org)
Graft versus1
- We present a case of acute myeloid leukemia developing acute graft-versus-host-disease (GVHD) in the post transplant phase. (bvsalud.org)
Donor1
- T-cell-depleted allogeneic transplant without donor leukocyte infusions results in excellent long-term survival in patients with multiply relapsed Lymphoma. (uchicago.edu)
Mortality1
- The profile of the clinical variables presented by the children and adolescents of this study shows that the most prevalent diagnosis was ALL, the most frequent toxicities were gastrointestinal, cardiac, respiratory and hematological, the most common HSCT was allogeneic peripheral blood and the greatest cause of mortality was sepsis. (bvsalud.org)
Bone marrow1
- The bone marrow in patients with LAD is hyperplastic, and some T-cell function is present. (medscape.com)
Engraftment2
- The absence of LFA-1 on host's cells that cause decreased T-cell function, T-cell cytotoxicity, and natural killer (NK) cell cytotoxicity may actually facilitate engraftment. (medscape.com)
- Allogeneic stem cell transplant in renal failure: engraftment and prolonged survival, but high incidence of neurologic toxicity. (uchicago.edu)
Trials1
- Five databases (PubMed, Embase, the Web of Science, the Cochrane Library, and Clinical Trials.gov) were searched from their inception dates to February 2021. (biomedcentral.com)
Immune1
- Ocular GVHD (oGVHD) is characterized by a T cell-mediated immune response that leads to immune cell infiltration and inflammation of ocular structures, including the lacrimal glands, eyelids, cornea and conjunctiva. (bvsalud.org)
Survival1
- Predictors for survival after transplant relapse. (uchicago.edu)
GVHD2
- Patterns and kinetics of T-cell chimerism after allo transplant with alemtuzumab-based conditioning: mixed chimerism protects from GVHD, but does not portend disease recurrence. (uchicago.edu)
- In this Blood Spotlight, we review recent research that addresses the critical failures in tissue regeneration and repair that underpin treatment-resistant GVHD. (bvsalud.org)
Treatment2
- In the animal studies, the disease activity index dramatically decreased in the mesenchymal stem cell (MSC) treatment groups compared to the control group. (biomedcentral.com)
- The clinical course, treatment and pathological findings on autopsy including the cause of death have been discussed. (bvsalud.org)
Biology1
- In recent years, developments in stem cell (SC) biology and regenerative medicine have revealed that SCs unexpectedly can be used to treat autoimmune diseases. (biomedcentral.com)
Therapeutic1
- Here, we review the pathophysiology and clinical presentation of oGVHD, along with current therapeutic strategies based on our clinical experience and the reported literature. (bvsalud.org)
Patients2
- We explored whether stem cell therapy was effective for animal models and patients with Crohn's disease (CD). (biomedcentral.com)
- Phase II study of immunomodulation with granulocyte-macrophage colony-stimulating factor, interleukin-2, and rituximab following autologous stem cell transplant in patients with relapsed or refractory lymphomas. (uchicago.edu)
Results1
- Several studies have evaluated the safety and effectiveness of CD stem cell therapy, but the results remain controversial. (biomedcentral.com)
Patient1
- clinical conditions of the patient, the existence of a tumors are considered rare (KLUSMANN et al. (bvsalud.org)
Type1
- [ 8 ] Deficiency of CD18 on phagocytic cells causes LAD type 1 (see Table 2). (medscape.com)
Hematopoietic cell transplantation2
- Studies of clinical and immunologic aspects of allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning. (nih.gov)
- 11. Generation of donor natural killer cells from CD34(+) progenitor cells and subsequent infusion after HLA-mismatched allogeneic hematopoietic cell transplantation: a feasibility study. (nih.gov)
Acute Lymphobl1
- This is a Phase I dose-finding study of FT819 as monotherapy and in combination with IL-2 in subjects with relapsed/refractory B-cell Lymphoma, Chronic Lymphocytic Leukemia and Precursor B-cell Acute Lymphoblastic Leukemia. (hpscreg.eu)
Progenitor cells1
- The allogeneic HSCT was the most frequently performed (57.14%) and the most used source of Hematopoietic progenitor cells (HPC) was the peripheral blood (54.29%) and 5.71% of these patients developed the Graft versus Host Disease (GVHD), of which one was affected by acute GVHD and another by chronic GVHD. (bvsalud.org)
Remission8
- The infusions were safe and well tolerated when given during clinical remission. (multiplesclerosistreatmentreport.com)
- The persistence of mutated NPM1 or FLT3 -ITD in the blood of adult patients with AML in first complete remission (CR1) prior to allogeneic hematopoetic cell transplant (alloHCT) has been established as associated with increased relapse and death after transplant. (bvsalud.org)
- Importance: Preventing relapse for adults with acute myeloid leukemia (AML) in first remission is the most common indication for allogeneic hematopoietic cell transplant. (bvsalud.org)
- Objective: To determine whether DNA sequencing to identify residual variants in the blood of adults with AML in first remission before allogeneic hematopoietic cell transplant identifies patients at increased risk of relapse and poorer overall survival compared with those without these DNA variants. (bvsalud.org)
- Design, Setting, and Participants: In this retrospective observational study, DNA sequencing was performed on pretransplant blood from patients aged 18 years or older who had undergone their first allogeneic hematopoietic cell transplant during first remission for AML associated with variants in FLT3, NPM1, IDH1, IDH2, or KIT at 1 of 111 treatment sites from 2013 through 2019. (bvsalud.org)
- Exposure: Centralized DNA sequencing of banked pretransplant remission blood samples. (bvsalud.org)
- Among 371 patients in the discovery cohort, the persistence of NPM1 and/or FLT3-ITD variants in the blood of 64 patients (17.3%) in remission before undergoing transplant was associated with worse outcomes after transplant (2013-2017). (bvsalud.org)
- Conclusions and Relevance: Among patients with acute myeloid leukemia in first remission prior to allogeneic hematopoietic cell transplant, the persistence of FLT3 internal tandem duplication or NPM1 variants in the blood at an allele fraction of 0.01% or higher was associated with increased relapse and worse survival compared with those without these variants. (bvsalud.org)
Peripheral2
- The profile of the clinical variables presented by the children and adolescents of this study shows that the most prevalent diagnosis was ALL, the most frequent toxicities were gastrointestinal, cardiac, respiratory and hematological, the most common HSCT was allogeneic peripheral blood and the greatest cause of mortality was sepsis. (bvsalud.org)
- We conducted a phase I clinical study assessing safety and clinical and peripheral immune responses after MSC therapy in MS. Seven patients with progressive MS were intravenously infused with a single dose of autologous MSC (1-2 × 106 MSCs/kg body weight). (multiplesclerosistreatmentreport.com)
Immunotherapy3
- 4. Characterization of natural killer and natural killer-like T cells derived from ex vivo expanded and activated cord blood mononuclear cells: implications for adoptive cellular immunotherapy. (nih.gov)
- 7. Pre-emptive immunotherapy with purified natural killer cells after haploidentical SCT: a prospective phase II study in two centers. (nih.gov)
- Subjects who previously took part in the FT500-101 study and received allogeneic NK cell immunotherapy will take part in this long term follow-up study. (hpscreg.eu)
20191
- We performed testing for residual IDH1 variants ( IDH1 m) in pre-transplant CR1 blood of 148 adult patients undergoing alloHCT for IDH1 -mutated AML at a CIBMTR site between 2013-2019. (bvsalud.org)
Bone2
- Short and Long Term Clinical and Immunologic Follow up after Bone Marrow Mesenchymal Stromal Cell Therapy in Progressive Multiple Sclerosis-A Phase I Study. (multiplesclerosistreatmentreport.com)
- Bone marrow derived mesenchymal stromal cells (BM-MSCs) have emerged as a possible new therapy for Multiple Sclerosis (MS), however studies regarding efficacy and in vivo immune response have been limited and inconclusive. (multiplesclerosistreatmentreport.com)
Phase I clinical study1
- 1. Safety analysis of ex vivo-expanded NK and NK-like T cells administered to cancer patients: a phase I clinical study. (nih.gov)
Lineages2
- Clonal hematopoietic stem cell disorders characterized by dysplasia in one or more hematopoietic cell lineages. (curehunter.com)
- Transplanted iNSCs differentiated along astrocyte and oligodendrocyte lineages, without myelinating, and many remained neural stem cells. (multiplesclerosistreatmentreport.com)
Therapies5
- Directly reprogramming fibroblasts into iNSCs facilitates the future translation towards exogenous autologous cell therapies. (multiplesclerosistreatmentreport.com)
- Educational experiences combining clinical CTL staff, medical director, and quality and regulatory team perspectives can provide a well-rounded approach for potential future medical directors of clinical CTLs or TM services handling existing and developing cell therapies in the clinical realm. (aabb.org)
- The success and trajectory of established and novel cell therapies and nature of CP and BB/TM training to prepare medical directors underscores the importance of including formal and dedicated educational CTL experiences in CP and BB/TM training programs. (aabb.org)
- However, the cancer cell therapy space has become very crowded and drug developers are currently seeking to expand the field into autoimmunity, with biotech and pharmaceutical companies employing a variety of strategies to develop differentiated cellular therapies against autoimmune diseases that present a huge unmet need. (alacrita.com)
- Newer, more targeted therapies aim to neutralize key proinflammatory cytokines, interfere with and inhibit the activation of lymphocytes, or enhance the pathways that suppress these cells. (alacrita.com)
Pathology1
- Clinical cell therapy laboratories (CTLs) that minimally manipulate products are part of many transfusion medicine (TM) services overseen by CTL medical directors with graduate medical education (GME) training in clinical pathology (CP) and/or blood banking and transfusion medicine (BB/TM). (aabb.org)
Outcomes1
- Each of the abstracts selected for this year's session addresses an emergent topic in transfusion medicine, such as patient outcomes based on blood donor sex and platelet bacterial detection. (aabb.org)
Predominantly1
- The cell therapy field has been predominantly active in the oncology space and is enjoying bench-to-bedside clinical success. (alacrita.com)
Inflammatory1
- Infectious sites are typically devoid of inflammatory cells. (medscape.com)
Immune2
- Importantly, there is a pressing need for therapeutic drugs that specifically target pathogenic cells whilst leaving the remainder of the immune system functioning normally. (alacrita.com)
- Recent drugs in development are focusing on promoting the induction and expansion of cells known to confer immune tolerance. (alacrita.com)
Study3
- These data, from the largest study to date, do not support the detection of IDH1 mutation in CR1 blood prior to alloHCT as evidence of AML MRD or increased post-transplant relapse risk. (bvsalud.org)
- The clinical study database aims at providing a comprehensive overview of clinical studies that specifically use human pluripotent stem cells (hPSC) or hPSC-derived cells. (hpscreg.eu)
- This is a phase 1 study of FT522 administered with rituximab in participants with relapsed/refractory B-cell lymphoma (R/R BCL). (hpscreg.eu)
Human1
- 6. Evaluation of ex vivo expanded human NK cells on antileukemia activity in SCID-beige mice. (nih.gov)
Research1
- Clinical data were collected, through May 2022, by the Center for International Blood and Marrow Transplant Research. (bvsalud.org)
Studies1
- Welcome to the clinical studies database on hPSCreg. (hpscreg.eu)
Profile1
- To characterize the clinical and epidemiological profile of children and adolescents submitted to HSCT at a referral service in the state of Rio Grande do Norte. (bvsalud.org)